Tsuruta Yoshinari, Ohbayashi Takaaki, Fujii Mikiko, Myochin Hisashi, Mizutani Ryoko, Narita Masayasu, Maeda Kenji
Division of Nephrology, Meiyo Clinic Hemodialysis Center, Japan.
Ther Apher Dial. 2008 Oct;12 Suppl 1:S34-7. doi: 10.1111/j.1744-9987.2008.00629.x.
We examined the influence of cinacalcet on vascular calcification by measuring the coronary artery calcification score (CACS) in hemodialysis patients who received cinacalcet. The cinacalcet treatment group consisted of eight hemodialysis patients with secondary hyperparathyroidism who received cinacalcet for 7-14 months. The mean CACS change in the treatment group was -0.094/year, showing a decreasing tendency, while that in the control group showed an increasing tendency of 0.034/year. The mean CACS change showed a tendency for improvement in the treatment group, but no significant difference from that in the control group was observed as the number of cases was small (P = 0.102). The results of this study suggest that cinacalcet is effective in preventing the progress of extraosseous calcification.
我们通过测量接受西那卡塞治疗的血液透析患者的冠状动脉钙化评分(CACS),研究了西那卡塞对血管钙化的影响。西那卡塞治疗组由8例继发性甲状旁腺功能亢进的血液透析患者组成,他们接受了7至14个月的西那卡塞治疗。治疗组的平均CACS变化为每年-0.094,呈下降趋势,而对照组则呈每年0.034的上升趋势。治疗组的平均CACS变化有改善的趋势,但由于病例数较少,与对照组相比无显著差异(P = 0.102)。本研究结果表明,西那卡塞在预防骨外钙化进展方面是有效的。